Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Regression of experimental medulloblastoma following transfer of HER2-specific T cells.

Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S.

Cancer Res. 2007 Jun 15;67(12):5957-64.

2.

Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.

Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML.

Clin Cancer Res. 2007 Mar 15;13(6):1883-91.

3.

HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.

Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S.

Clin Cancer Res. 2010 Jan 15;16(2):474-85. doi: 10.1158/1078-0432.CCR-09-1322. Epub 2010 Jan 12.

4.

[Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].

Li SP, Urban FA, Macgregor JN, Hughes DP, McDonagh KT.

Ai Zheng. 2004 Nov;23(11 Suppl):1370-5. Chinese.

PMID:
15566639
5.

Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.

Knutson KL, Disis ML.

Clin Breast Cancer. 2001 Apr;2(1):73-9. Review.

PMID:
11899386
6.

Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines.

Bernardi RJ, Lowery AR, Thompson PA, Blaney SM, West JL.

J Neurooncol. 2008 Jan;86(2):165-72. Epub 2007 Sep 6.

PMID:
17805488
7.

Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.

Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nährig J, Fend F, Weber W, Busch DH, Peschel C.

Cancer Immunol Immunother. 2008 Feb;57(2):271-80. Epub 2007 Jul 24.

PMID:
17646988
9.

An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2.

Nabekura T, Nagasawa T, Nakauchi H, Onodera M.

Cancer Immunol Immunother. 2008 May;57(5):611-22. Epub 2007 Sep 5.

PMID:
17786440
10.

Tumor ablation by gene-modified T cells in the absence of autoimmunity.

Wang LX, Westwood JA, Moeller M, Duong CP, Wei WZ, Malaterre J, Trapani JA, Neeson P, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Res. 2010 Dec 1;70(23):9591-8. doi: 10.1158/0008-5472.CAN-10-2884. Epub 2010 Nov 23.

11.

Construction and evaluation of a novel humanized HER2-specific chimeric receptor.

Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y.

Breast Cancer Res. 2014 Jun 11;16(3):R61. doi: 10.1186/bcr3674.

12.

Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.

Ishida A, Tanaka H, Hiura T, Miura S, Watanabe S, Matsuyama K, Kuriyama H, Tanaka J, Kagamu H, Gejyo F, Yoshizawa H.

Scand J Immunol. 2007 Nov;66(5):546-54.

13.

Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.

Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.

Clin Cancer Res. 2009 Jul 15;15(14):4612-21. doi: 10.1158/1078-0432.CCR-08-3321. Epub 2009 Jul 7.

14.

Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.

Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG.

Clin Cancer Res. 2006 Jan 15;12(2):569-76.

16.

Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction.

Nechushtan H, Pham D, Zhang Y, Morgensztern D, Yi KH, Shin SU, Federoff HJ, Bowers WJ, Tolba KA, Rosenblatt JD.

Cancer Immunol Immunother. 2008 May;57(5):663-75. Epub 2007 Oct 19.

PMID:
17952436
17.

Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.

Stastny MJ, Brown CE, Ruel C, Jensen MC.

J Pediatr Hematol Oncol. 2007 Oct;29(10):669-77.

PMID:
17921847
18.
19.

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.

Yoon SH, Lee JM, Cho HI, Kim EK, Kim HS, Park MY, Kim TG.

Cancer Gene Ther. 2009 Jun;16(6):489-97. doi: 10.1038/cgt.2008.98. Epub 2008 Dec 19.

PMID:
19096447
20.

Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.

Rainusso N, Brawley VS, Ghazi A, Hicks MJ, Gottschalk S, Rosen JM, Ahmed N.

Cancer Gene Ther. 2012 Mar;19(3):212-7. doi: 10.1038/cgt.2011.83. Epub 2011 Dec 16.

PMID:
22173710

Supplemental Content

Support Center